Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB05039_DB06216> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB05039_DB06216 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB05039_DB06216 label "DDI between Indacaterol and Asenapine - Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. [drugbank_resource:DB05039_DB06216]" assertion.
- drugbank_resource:DB05039_DB06216 identifier "drugbank_resource:DB05039_DB06216" assertion.
- drugbank_resource:DB05039_DB06216 title "DDI between Indacaterol and Asenapine - Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system." assertion.